EpiPen Buyers Target Mylan CEO After Teva Disclosures
Consumers are demanding another deposition of Mylan's CEO as part of multidistrict litigation over skyrocketing EpiPen prices, citing allegedly incriminating documents produced by Teva Pharmaceuticals in recent weeks....To view the full article, register now.
Already a subscriber? Click here to view full article